Danwen Yang
Nephrology · Bridgeport, CTNPI 1154740306
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 288 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,487, 8.4 times the $176 reported in 2019.
Across 288 payments — averaging $23.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$909
- Travere Therapeutics, Inc.$525
- Vifor Pharma, Inc.$513
- Mallinckrodt Hospital Products Inc.$443
- Otsuka America Pharmaceutical, Inc.$389
- plus $3K from 18 others
What the payments were for
- Food & beverage$6,59098%
- Education$1212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 48 | $1,102 |
| Amgen(2 entities) | 38 | $909 |
| Travere Therapeutics, Inc. | 24 | $525 |
| Vifor Pharma, Inc. | 19 | $513 |
| Mallinckrodt Hospital Products Inc. | 17 | $443 |
| Otsuka America Pharmaceutical, Inc. | 15 | $389 |
| Novo Nordisk | 13 | $324 |
| Akebia Therapeutics Inc | 13 | $318 |
| Ardelyx, Inc. | 15 | $300 |
| Bayer | 11 | $266 |
| GSK | 14 | $264 |
| Boehringer Ingelheim | 10 | $221 |
| Calliditas Therapeutics US Inc. | 8 | $221 |
| Fresenius USA Marketing, Inc. | 10 | $197 |
| Aurinia Pharma U.S., Inc. | 8 | $186 |
| Xeris Pharmaceuticals, Inc. | 8 | $150 |
| Sanofi | 6 | $141 |
| Kyowa Kirin, Inc. | 3 | $61 |
| Alnylam Pharmaceuticals Inc. | 2 | $48 |
| Lilly USA, LLC | 2 | $40 |
| Apellis Pharmaceuticals, Inc. | 1 | $33 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $20 |
| Cormedix Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,711 in reported general payments places this provider in the 85th percentile of 144 nephrology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 137 | $167,012 |
| JardianceEmpagliflozin | 18 | $30,327 |
| VelphoroSucroferric Oxyhydroxide | 12 | $16,138 |
| Sevelamer Carbonate | 46 | $10,853 |
| Torsemide | 23 | $1,000 |
| Losartan Potassium | 45 | $259 |
| Amlodipine Besylate | 48 | $163 |
| Famotidine | 11 | $139 |
| Hydrochlorothiazide | 25 | $130 |
| Hydralazine Hcl | 17 | $113 |
| Allopurinol | 22 | $106 |
| Carvedilol | 17 | $95 |
| Lisinopril | 15 | $90 |
| Potassium Chloride | 16 | $76 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 11 | $72 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $1,102 | $167,012137 claims |
| Boehringer IngelheimJardiance | $221 | $30,32718 claims |
| Fresenius USA Marketing, Inc.Velphoro | $197 | $16,13812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 144 nephrology providers in Connecticut.
Other nephrology in Bridgeport
- Robert AlpernNew Haven$4.9M
- Ari GellerBloomfield$209K
- Richard FormicaNew Haven$198K
- Stefan SomloNew Haven$111K
- James GavinTrumbull$103K
- Fredric FinkelsteinNew Haven$70K
- Justin BelcherNew Haven$59K
- David SimonOrange$59K
- Ladan GolestanehNew Haven$54K
- Sharad SathyanBloomfield$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.